866-997-4948(US-Canada Toll Free)

Colon Cancer - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Cancer

No. of Pages : 492 Pages

Global Markets Direct’s, ‘Colon Cancer - Pipeline Review, H1 2014’, provides an overview of the Colon Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Colon Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Colon Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Colon Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Colon Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Introduction

Colon Cancer Overview
Therapeutics Development
Colon Cancer - Therapeutics under Development by Companies
Colon Cancer - Therapeutics under Investigation by Universities/Institutes
Colon Cancer - Pipeline Products Glance
Colon Cancer - Products under Development by Companies
Colon Cancer - Products under Investigation by Universities/Institutes
Colon Cancer - Companies Involved in Therapeutics Development
Colon Cancer - Therapeutics Assessment
Drug Profiles
Colon Cancer - Recent Pipeline Updates
Colon Cancer - Dormant Projects
Colon Cancer - Discontinued Products
Colon Cancer - Product Development Milestones

Appendix

List of Table


Number of Products under Development for Colon Cancer, H1 2014
Number of Products under Development for Colon Cancer - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Development by Companies, H1 2014 (Contd..3)
Number of Products under Development by Companies, H1 2014 (Contd..4)
Number of Products under Development by Companies, H1 2014 (Contd..5)
Number of Products under Development by Companies, H1 2014 (Contd..6)
Number of Products under Development by Companies, H1 2014 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2)
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Comparative Analysis by Unknown Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Development by Companies, H1 2014 (Contd..2)
Products under Development by Companies, H1 2014 (Contd..3)
Products under Development by Companies, H1 2014 (Contd..4)
Products under Development by Companies, H1 2014 (Contd..5)
Products under Development by Companies, H1 2014 (Contd..6)
Products under Development by Companies, H1 2014 (Contd..7)
Products under Development by Companies, H1 2014 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2014
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2)
Colon Cancer - Pipeline by AstraZeneca PLC, H1 2014
Colon Cancer - Pipeline by GlaxoSmithKline plc, H1 2014
Colon Cancer - Pipeline by Bioniche Life Sciences, Inc., H1 2014
Colon Cancer - Pipeline by Bavarian Nordic A/S, H1 2014
Colon Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014
Colon Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2014
Colon Cancer - Pipeline by Piramal Enterprises Limited, H1 2014
Colon Cancer - Pipeline by Celltrion, Inc., H1 2014
Colon Cancer - Pipeline by Bio-Path Holdings, Inc., H1 2014
Colon Cancer - Pipeline by Histogen, Inc., H1 2014
Colon Cancer - Pipeline by Geistlich Pharma AG, H1 2014
Colon Cancer - Pipeline by Aphios Corporation, H1 2014
Colon Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014
Colon Cancer - Pipeline by Eisai Co., Ltd., H1 2014
Colon Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2014
Colon Cancer - Pipeline Ono Pharmaceutical Co., Ltd., H1 2014
Colon Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2014
Colon Cancer - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2014
Colon Cancer - Pipeline by Immunomedics, Inc., H1 2014
Colon Cancer - Pipeline by Genfit SA, H1 2014
Colon Cancer - Pipeline by Lorus Therapeutics Inc., H1 2014
Colon Cancer - Pipeline by Bionomics Limited, H1 2014
Colon Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2014
Colon Cancer - Pipeline by Compugen Ltd., H1 2014
Colon Cancer - Pipeline by Patrys Limited, H1 2014
Colon Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2014
Colon Cancer - Pipeline by Dendreon Corporation, H1 2014
Colon Cancer - Pipeline by Progen Pharmaceuticals Limited, H1 2014
Colon Cancer - Pipeline by JW Pharmaceutical Corporation, H1 2014
Colon Cancer - Pipeline by Green Cross Corporation, H1 2014
Colon Cancer - Pipeline by Sareum Holdings plc, H1 2014
Colon Cancer - Pipeline by Microbio Co., Ltd., H1 2014
Colon Cancer - Pipeline by Transgene Biotek Limited, H1 2014
Colon Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2014
Colon Cancer - Pipeline by MabVax Therapeutics, Inc., H1 2014
Colon Cancer - Pipeline by Nanobiotix, H1 2014
Colon Cancer - Pipeline by Aurigene Discovery Technologies Limited, H1 2014
Colon Cancer - Pipeline by Supratek Pharma Inc., H1 2014
Colon Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014
Colon Cancer - Pipeline by Quantum Pharmaceuticals, H1 2014
Colon Cancer - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2014
Colon Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H1 2014
Colon Cancer - Pipeline by Med Discovery SA, H1 2014
Colon Cancer - Pipeline by Priaxon AG, H1 2014
Colon Cancer - Pipeline by Provecs Medical GmbH, H1 2014
Colon Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2014
Colon Cancer - Pipeline by Kalos Therapeutics, Inc., H1 2014
Colon Cancer - Pipeline by AlphaVax, Inc., H1 2014
Colon Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2014
Colon Cancer - Pipeline by Mersana Therapeutics, Inc., H1 2014
Colon Cancer - Pipeline by Affichem, H1 2014
Colon Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2014
Colon Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2014
Colon Cancer - Pipeline by Pharminox Limited, H1 2014
Colon Cancer - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2014
Colon Cancer - Pipeline by Immunotope, Inc., H1 2014
Colon Cancer - Pipeline by Omeros Corporation, H1 2014
Colon Cancer - Pipeline by Vaccinogen, Inc., H1 2014
Colon Cancer - Pipeline by Etubics Corporation, H1 2014
Colon Cancer - Pipeline by NewLink Genetics Corporation, H1 2014
Colon Cancer - Pipeline by Cellceutix Corporation, H1 2014
Colon Cancer - Pipeline by Pharma Mar, S.A., H1 2014
Colon Cancer - Pipeline by TVAX Biomedical, Inc., H1 2014
Colon Cancer - Pipeline by Biokine Therapeutics Ltd., H1 2014
Colon Cancer - Pipeline by Tautatis Incorporated, H1 2014
Colon Cancer - Pipeline by Viventia Biotechnologies Inc., H1 2014
Colon Cancer - Pipeline by Merus B.V., H1 2014
Colon Cancer - Pipeline by Pique Therapeutics, H1 2014
Colon Cancer - Pipeline by Sunshine Biopharma, Inc., H1 2014
Colon Cancer - Pipeline by Isofol Medical AB, H1 2014
Colon Cancer - Pipeline by Incuron, LLC, H1 2014
Colon Cancer - Pipeline by DEKK-TEC, Inc., H1 2014
Colon Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2014
Colon Cancer - Pipeline by Mabion SA, H1 2014
Colon Cancer - Pipeline by SentoClone International AB, H1 2014
Colon Cancer - Pipeline by GlycaNova Norway AS, H1 2014
Colon Cancer - Pipeline by EntreChem, S.L., H1 2014
Colon Cancer - Pipeline by Cold Genesys, Inc., H1 2014
Colon Cancer - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H1 2014
Colon Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2014
Colon Cancer - Pipeline by PsiOxus Therapeutics, Ltd., H1 2014
Colon Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014
Colon Cancer - Pipeline by CureFAKtor Pharmaceuticals. LLC, H1 2014
Colon Cancer - Pipeline by Kancera AB, H1 2014
Colon Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2014
Colon Cancer - Pipeline by Orega Biotech SAS, H1 2014
Colon Cancer - Pipeline by Qu Biologics Inc., H1 2014
Colon Cancer - Pipeline by CZ BioMed Corp, H1 2014
Colon Cancer - Pipeline by IMPACT Therapeutics, Inc., H1 2014
Colon Cancer - Pipeline by CytomX Therapeutics, Inc., H1 2014
Colon Cancer - Pipeline by Panacela Labs, Inc., H1 2014
Colon Cancer - Pipeline by bioXPRESS Therapeutics SA, H1 2014
Colon Cancer - Pipeline by Medicon Pharmaceuticals, Inc, H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Colon Cancer Therapeutics - Recent Pipeline Updates, H1 2014
Colon Cancer - Dormant Projects, H1 2014
Colon Cancer - Discontinued Products, H1 2014

List of Chart


Number of Products under Development for Colon Cancer, H1 2014
Number of Products under Development for Colon Cancer - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *